About Terminal nucleotidyltransferase 5B
Terminal nucleotidyltransferase 5B (TENT5B) is a protein
from Homo sapiens identified by UniProt accession
Q96A09, 425 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | Terminal nucleotidyltransferase 5B |
| UniProt accession | Q96A09 |
| Gene | TENT5B |
| Organism | Homo sapiens |
| Length | 425 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (56)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.24
- vitamin D measurement · score 0.19
- low density lipoprotein cholesterol measurement · score 0.15
- leukocyte count · score 0.11
- Hypercholesterolemia · score 0.09
- reticulocyte count · score 0.07
- testosterone measurement · score 0.06
- sex hormone-binding globulin measurement · score 0.06
- pachyonychia congenita · score 0.06
- gout · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96A09-F1 | alphafold | PREDICTED | 81.82 | — |
Amino-acid sequence (425 residues)
MMPSESGAER RDRAAAQVGT AAATAVATAA PAGGGPDPEA LSAFPGRHLS GLSWPQVKRL DALLSEPIPI HGRGNFPTLS VQPRQIVQVV RSTLEEQGLH VHSVRLHGSA ASHVLHPESG LGYKDLDLVF RVDLRSEASF QLTKAVVLAC LLDFLPAGVS RAKITPLTLK EAYVQKLVKV CTDSDRWSLI SLSNKSGKNV ELKFVDSVRR QFEFSIDSFQ IILDSLLLFG QCSSTPMSEA FHPTVTGESL YGDFTEALEH LRHRVIATRS PEEIRGGGLL KYCHLLVRGF RPRPSTDVRA LQRYMCSRFF IDFPDLVEQR RTLERYLEAH FGGADAARRY ACLVTLHRVV NESTVCLMNH ERRQTLDLIA ALALQALAEQ GPAATAALAW RPPGTDGVVP ATVNYYVTPV QPLLAHAYPT WLPCN
Explore Terminal nucleotidyltransferase 5B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets